Active Ingredient History
Sugammadex (ORG 25969) is a cyclodextrin derivative was synthesized as synthetic receptor (or host molecule) for neuromuscular blockers (rocuronium and vecuronium). It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium and vecuronium. The clinical use of sugammadex promises to eliminate many of the shortcomings in current anesthetic practice with regard to antagonism of rocuronium and other aminosteroid muscle relaxants. Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute-On-Chronic Liver Failure (Phase 4)
Anaphylaxis (Phase 1)
Anesthesia (Phase 4)
Anesthesia and Analgesia (Phase 4)
Anesthesia, General (Phase 4)
Anesthesia Recovery Period (Phase 4)
Anesthesia, Spinal (Phase 4)
Anesthesiology (Phase 4)
Arthroplasty, Replacement, Hip (Phase 3)
Arthroplasty, Replacement, Knee (Phase 3)
Bariatric Surgery (Phase 3)
beta-Thalassemia (Phase 2/Phase 3)
Blood Coagulation (Phase 3)
Blood Pressure (Phase 4)
Brain Neoplasms (Phase 4)
Bronchoscopy (Phase 4)
Burns (Phase 3)
Cervix Uteri (Phase 4)
Cesarean Section (Phase 4)
Cholecystectomy, Laparoscopic (Phase 4)
Cholecystitis (Phase 4)
Coronary Artery Disease (Phase 4)
Delayed Emergence from Anesthesia (Phase 4)
Diaphragm (Phase 3)
Elective Surgical Procedures (Phase 3)
Electromyography (Phase 4)
Emergence Delirium (Phase 4)
Endometriosis (Phase 4)
Extracorporeal Membrane Oxygenation (Phase 4)
Fibrinolytic Agents (Phase 3)
Gallbladder Diseases (Phase 4)
General Surgery (Phase 4)
Gynecology (Phase 4)
Hepatoblastoma (Phase 3)
High-Frequency Jet Ventilation (Phase 1)
Hip Fractures (Phase 4)
Hypersensitivity (Phase 1)
Intestinal Diseases (Phase 4)
Kidney Diseases (Phase 1)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 4)
Laparoscopy (Phase 4)
Laryngoscopy (Phase 4)
Leiomyoma (Phase 4)
Liver Diseases (Phase 4)
Lung Diseases (Phase 4)
Lymphoma (Phase 3)
Mobility Limitation (Phase 4)
Muscle Fatigue (Phase 3)
Muscle Relaxants, Central (Phase 4)
Muscle Relaxation (Phase 4)
Muscle Weakness (Phase 3)
Nausea (Phase 4)
Neoplasm Metastasis (Phase 4)
Neoplasms (Phase 4)
Neostigmine (Phase 4)
Neuromuscular Blockade (Phase 4)
Obesity (Phase 4)
Obesity, Morbid (Phase 2/Phase 3)
Organophosphate Poisoning (Phase 2/Phase 3)
Pain, Postoperative (Phase 4)
Pharmacokinetics (Phase 4)
Pneumoperitoneum (Phase 4)
Postoperative Complications (Phase 4)
Postoperative Nausea and Vomiting (Phase 4)
Pre-Eclampsia (Phase 4)
Pregnancy (Phase 4)
Prostatic Neoplasms (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Rapid Sequence Induction and Intubation (Phase 4)
Renal Insufficiency (Phase 1)
Renal Insufficiency, Chronic (Phase 4)
Respiratory-Gated Imaging Techniques (Phase 4)
Respiratory Insufficiency (Phase 4)
Respiratory Muscles (Phase 4)
Rocuronium (Phase 4)
Sleep Apnea, Obstructive (Phase 4)
Spinal Curvatures (Phase 4)
Spinal Diseases (Phase 4)
Sugammadex (Phase 4)
Ultrasonography (Phase 4)
Urinary Bladder Neoplasms (Phase 4)
Uterine Prolapse (Phase 4)
Ventilators, Mechanical (Phase 4)
Vocal Cord Dysfunction (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
